(Q44375182)

2 December 2017

title

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial (English)

1 reference

Adaptive radiation therapy

2 December 2017

main subject

0 references

1 reference

10

1 reference

2 December 2017

John D Graham

3

0 references

Richard A. Cowan

object named as

Richard A Cowan

6

0 references

Matthew R Sydes

object named as

Matthew R Sydes

2

0 references

author name string

David P Dearnaley

1

1 reference

2 December 2017

Edwin G Aird

4

1 reference

2 December 2017

David Bottomley

5

1 reference

2 December 2017

Robert A Huddart

7

1 reference

2 December 2017

Chakiath C Jose

8

1 reference

2 December 2017

John Hl Matthews

9

1 reference

2 December 2017

A Rollo Moore

11

1 reference

2 December 2017

Rachel C Morgan

12

1 reference

2 December 2017

J Martin Russell

13

1 reference

2 December 2017

Christopher D Scrase

14

1 reference

2 December 2017

Richard J Stephens

15

1 reference

2 December 2017

Isabel Syndikus

16

1 reference

2 December 2017

Mahesh K B Parmar

17

1 reference

2 December 2017

RT01 collaborators

18

1 reference

2 December 2017

publication date

1 June 2007

1 reference

Lancet Oncology Commission

2 December 2017

published in

1 reference

2 December 2017

volume

8

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

475-487

1 reference

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Active surveillance: towards a new paradigm in the management of early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Technological advances in radiotherapy for the treatment of localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate--analysis of RTOG study 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Eradication of a disease: how we cured symptomless prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The management of PSA failure after radical radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Do patients with localized prostate cancer treatment really want more aggressive treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be diffic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970143-2

7 January 2021

10.1016/S1470-2045(07)70143-2

Identifiers

DOI

1 reference

2 December 2017

1 reference